Back to discover

Protein / target

Proto-oncogene Mas

Encoded byMAS1P04201Homo sapiensSwiss-Prot
UniProt: P04201Ensembl: ENSG00000130368HGNC: HGNC:6899NCBI Gene: 4142
Clinical-stage
Therapeutic maturity
1
Clinical candidates
Small-molecule tractable
Druggability
Druggable Family
2
Research papers

Protein at a glance

Biological role

Angiotensin type II receptor

Strongest disease association

Hypertension

Via encoding gene MAS1 · Genetic evidence · score 0.52

Therapeutic position

Clinically advancing target

Research activity

Emerging research

2 papers · latest 2025

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

G protein-coupled receptor that plays key roles in the renin-angiotensin system (RAS) specifically in the protective, counter-regulatory arm of the RAS.

View complete UniProt function annotation

G protein-coupled receptor that plays key roles in the renin-angiotensin system (RAS) specifically in the protective, counter-regulatory arm of the RAS (PubMed:25967876). Receptor mainly stimulated by angiotensin 1-7, which is a bioactive metabolite of the angiotensin produced by ACE2 (PubMed:17984366). Activation promotes nitric oxide via PI3K/Akt-eNOS pathway (PubMed:17984366). Modulates also the MAPK, ERK1/2, and NF-kappa-B signaling (PubMed:25967876). Positive regulation of AGTR1 levels occurs through activation of the G proteins GNA11 and GNAQ, and stimulation of the protein kinase C signaling cascade (PubMed:15809376, PubMed:16611642). The antagonist effect on AGTR1 function is probably due to AGTR1 being physically altered by MAS1 (PubMed:15809376, PubMed:16611642). Acts as functional receptor for CXCL17 and induces chemotactic movement (PubMed:41167449)

Subcellular location

Cell membrane
Domains and Gene Ontology detail (12)

Gene Ontology

  • Cplasma membrane
  • Fangiotensin receptor activity
  • Fangiotensin type II receptor activity
  • FC-C chemokine receptor activity
  • FG protein-coupled receptor activity
  • Fpeptide binding
  • Padenylate cyclase-activating G protein-coupled receptor signaling pathway
  • Pangiotensin-mediated vasodilation involved in regulation of systemic arterial blood pressure
  • Pcell migration
  • Pchemokine-mediated signaling pathway
  • PG protein-coupled receptor signaling pathway
  • Pphospholipase C-activating angiotensin-activated signaling pathway

325 aa · 37 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationGOG protein-coupled signallingUniProt · GO
View supporting evidence

Cell migration

  • ·cell migration

G protein-coupled signalling

  • ·G protein-coupled receptor that plays key roles in the renin-angiotensin system (RAS) sp…
  • ·G protein-coupled receptor activity
  • ·adenylate cyclase-activating G protein-coupled receptor signaling pathway
  • ·G protein-coupled receptor signaling pathway

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene MAS1

Gene-level evidence surfaced through the gene MAS1that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Hypertension
0.56Moderately supported

Genetic evidence dominant · Open Targets 0.33

Placental abruption
0.46Limited support

Genetic evidence dominant · Open Targets 0.28

Essential Hypertension
0.38Limited support

Genetic evidence dominant · Open Targets 0.22

COVID-19
0.33Limited support

Clinical evidence dominant · Open Targets 0.25

Coronary Artery Disease
0.24Preliminary

Genetic evidence dominant · Open Targets 0.14

View evidence synthesis (5)
HypertensionModerately supported
0.56
agreement 0.46–0.67
Genetic84%Literature11%Clinical5%

Open Targets aggregate 0.33 · 3 independent evidence families

Placental abruptionLimited support
0.46
agreement 0.34–0.58
Genetic100%

Open Targets aggregate 0.28 · 1 independent evidence family

Essential HypertensionLimited support
0.38
agreement 0.27–0.49
Genetic88%Clinical12%Literature1%

Open Targets aggregate 0.22 · 3 independent evidence families

COVID-19Limited support
0.33
agreement 0.17–0.48
Clinical92%Literature8%

Open Targets aggregate 0.25 · 2 independent evidence families

Coronary Artery DiseasePreliminary
0.24
agreement 0.10–0.38
Genetic96%Literature4%

Open Targets aggregate 0.14 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Hypertension0.33
Placental abruption0.28
COVID-190.25
Essential Hypertension0.22
Respiratory Insufficiency0.19
Coronary Artery Disease0.14
Alcohol drinking0.13

Drug development

1 compounds recorded · 1 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines.

View all recorded compounds (1)
TALFIRASTIDEPhase 3

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small molecules — Emerging

Feasibility evidence (druggable family) — no clinical-stage drug of this modality recorded.

Antibodies — Emerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degraders — Emerging

Feasibility evidence (small molecule binder) — no clinical-stage drug of this modality recorded.

Other modalities — Strong

Advanced Clinical support this modality.

View underlying tractability evidence (6)
SM · Druggable FamilyAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · Small Molecule BinderOC · Advanced Clinical

Raw Open Targets tractability assessment buckets, by modality.

Research activity

2 papers · to 2025

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications.167 cites

Trougakos IP · Journal of biomedical science · 2021

CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.3 cites

Raninga PV · Oncogene · 2025

Recent

CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.

Raninga PV · Oncogene · 2025

Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications.

Trougakos IP · Journal of biomedical science · 2021

Europe PMC papers linked directly to this protein.